Posted by Michael Wonder on 31 May 2020
Lilly's Cyramza (ramucirumab) receives FDA approval as first-line treatment for metastatic EGFR mutated non-small cell lung cancer
29 May 2020 - Cyramza, in combination with erlotinib, now approved for the treatment of people with untreated metastatic non-small cell lung cancer with certain activating EGFR mutations, based on the positive global Phase 3 RELAY study.
Eli Lilly and Company today announced that the U.S. FDA has approved Cyramza (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of people with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
With this approval, Cyramza has now received six FDA approvals to treat certain types of lung, liver, stomach and colorectal cancers.
